Palmer, DH;
Ma, YT;
Peck-Radosavljevic, M;
Ross, P;
Graham, J;
Fartoux, L;
Deptala, A;
... Meyer, T; + view all
(2018)
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
British Journal of Cancer
, 118
pp. 1162-1168.
10.1038/s41416-018-0051-8.
Preview |
Text (Article)
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.pdf - Published Version Download (805kB) | Preview |
Preview |
Text (Supplementary Data)
Meyer_41416_2018_51_MOESM1_ESM.pdf Download (149kB) | Preview |
Preview |
Image (Supplementary Figure S1Supplementary Figure S2)
Meyer_41416_2018_51_MOESM2_ESM.tif Download (1MB) | Preview |
Preview |
Image (Supplementary Figure S2)
Meyer_41416_2018_51_MOESM3_ESM.tif Download (763kB) | Preview |
Preview |
Image (Supplementary Figure S3)
Meyer_41416_2018_51_MOESM4_ESM.tif Download (414kB) | Preview |
Preview |
Text (Supplementary Table S1)
Meyer_41416_2018_51_MOESM5_ESM.pdf Download (179kB) | Preview |
Preview |
Text (Supplementary Table S2)
Meyer_41416_2018_51_MOESM6_ESM.pdf Download (20kB) | Preview |
Preview |
Text (Supplementary Table S3)
Meyer_41416_2018_51_MOESM7_ESM.pdf Download (107kB) | Preview |
Preview |
Text (Supplementary Table S4)
Meyer_41416_2018_51_MOESM8_ESM.pdf Download (135kB) | Preview |
Preview |
Text (Supplementary Table S5)
Meyer_41416_2018_51_MOESM9_ESM.pdf Download (20kB) | Preview |
Preview |
Text (Supplementary Table S6)
Meyer_41416_2018_51_MOESM10_ESM.pdf Download (16kB) | Preview |
Preview |
Text (Supplementary Table S7)
Meyer_41416_2018_51_MOESM11_ESM.pdf Download (60kB) | Preview |
Preview |
Text (Supplementary Table S8)
Meyer_41416_2018_51_MOESM12_ESM.pdf Download (196kB) | Preview |
Preview |
Text (Supplementary Table S9)
Meyer_41416_2018_51_MOESM13_ESM.pdf Download (255kB) | Preview |
Abstract
BACKGROUND: This multicentre, open-label, phase-I/randomised phase-II trial evaluated safety, pharmacokinetics, maximum-tolerated-dose (MTD) per dose-limiting toxicities (DLTs), and efficacy of nintedanib vs. sorafenib in European patients with unresectable advanced hepatocellular carcinoma (aHCC). METHODS: Phase I: Patients were stratified into two groups per baseline aminotransferase/alanine aminotransferase and Child-Pugh score; MTD was determined. Phase II: Patients were randomised 2:1 to nintedanib (MTD) or sorafenib (400-mg bid) in 28-day cycles until intolerance or disease progression. Time-to-progression (TTP, primary endpoint), overall survival (OS) and progression-free survival (PFS) were determined. RESULTS: Phase-I: no DLTs observed; nintedanib MTD in both groups was 200 mg bid. Phase-II: patients (N = 93) were randomised to nintedanib (n = 62) or sorafenib (n = 31); TTP was 5.5 vs. 4.6 months (HR = 1.44 [95% CI, 0.81-2.57]), OS was 11.9 vs. 11.4 months (HR = 0.88 [95% CI, 0.52-1.47]), PFS was 5.3 vs. 3.9 months (HR = 1.35 [95% CI, 0.78-2.34]), respectively (all medians). Dose intensity and tolerability favoured nintedanib. Fewer patients on nintedanib (87.1%) vs. sorafenib (96.8%) had drug-related adverse events (AEs) or grade ≥ 3 AEs (67.7% vs. 90.3%), but more patients on nintedanib (28 [45.2%]) had AEs leading to drug discontinuation than did those on sorafenib (7 [22.6%]). CONCLUSIONS: Nintedanib may have similar efficacy to sorafenib in aHCC.
| Type: | Article |
|---|---|
| Title: | A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/s41416-018-0051-8 |
| Publisher version: | https://doi.org/10.1038/s41416-018-0051-8 |
| Language: | English |
| Additional information: | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10045800 |
Archive Staff Only
 |
View Item |
